Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | UBE2M | P61081 | 4/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.36 |
| ▸ | TACR1 | P25103 | 5/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968674 | 0.85 | UBE2M (0.41) | MAPTUBE2MDCUN1D1TACR1XBP1 | |
| SCHEMBL1969545 | 0.85 | UBE2M (0.41) | MAPTUBE2MDCUN1D1TACR1XBP1 | |
| SCHEMBL1973929 | 0.82 | UBE2M (0.42) | MAPTUBE2MDCUN1D1TACR1CXCR3 | |
| SCHEMBL15397487 | 0.80 | TACR1 (0.43) | KDRMAPTUBE2MDCUN1D1TACR1 | |
| SCHEMBL1970589 | 0.80 | TACR1 (0.41) | MAPTUBE2MDCUN1D1TACR1XBP1 | |
| SCHEMBL1968683 | 0.80 | EPHX2 (0.42) | MAPTUBE2MDCUN1D1TACR1CXCR3 | |
| SCHEMBL1972469 | 0.80 | TACR1 (0.41) | MAPTUBE2MDCUN1D1TACR1XBP1 | |
| SCHEMBL1968873 | 0.80 | TACR1 (0.41) | MAPTUBE2MDCUN1D1TACR1XBP1 | |
| SCHEMBL1974193 | 0.78 | TACR1 (0.48) | MAPTUBE2MDCUN1D1TACR1CXCR3 | |
| SCHEMBL1969850 | 0.78 | RHOC (0.48) | MAPTUBE2MDCUN1D1TACR1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | KDR 972/4885CCKBR 6/4885MAPT 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.